Literature DB >> 27797957

Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action.

Yves Pommier1, Mark J O'Connor2, Johann de Bono3.   

Abstract

Poly(ADP-ribose) polymerase (PARP) inhibitors are the first DNA damage response targeted agents approved for cancer therapy. Here, we focus on their molecular mechanism of action by PARP "trapping" and what this means for both clinical monotherapy and combination with chemotherapeutic agents.
Copyright © 2016, American Association for the Advancement of Science.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27797957     DOI： 10.1126/scitranslmed.aaf9246

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN： 1946-6234            Impact factor:   17.956


  207 in total

Review 1.  RNase H2-RED carpets the path to eukaryotic RNase H2 functions.

Authors:  Susana M Cerritelli; Robert J Crouch
Journal:  DNA Repair (Amst)       Date:  2019-10-23

Review 2.  Targeting DNA repair in cancer: current state and novel approaches.

Authors:  Apostolos Klinakis; Dimitris Karagiannis; Theodoros Rampias
Journal:  Cell Mol Life Sci       Date:  2019-10-14       Impact factor: 9.261

3.  Modeling DNA trapping of anticancer therapeutic targets using missense mutations identifies dominant synthetic lethal interactions.

Authors:  Akil Hamza; Leanne Amitzi; Lina Ma; Maureen R M Driessen; Nigel J O'Neil; Philip Hieter
Journal:  Proc Natl Acad Sci U S A       Date:  2021-04-06       Impact factor: 11.205

Review 4.  Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer?

Authors:  Narjust Duma; Kelly C Gast; Grace M Choong; Roberto A Leon-Ferre; Ciara C O'Sullivan
Journal:  Curr Oncol Rep       Date:  2018-06-08       Impact factor: 5.075

Review 5.  Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.

Authors:  Katherine C Kurnit; Robert L Coleman; Shannon N Westin
Journal:  Curr Treat Options Oncol       Date:  2018-11-15

Review 6.  The DNA damage response pathway in normal hematopoiesis and malignancies.

Authors:  Domenico Delia; Shuki Mizutani
Journal:  Int J Hematol       Date:  2017-07-13       Impact factor: 2.490

Review 7.  Proteolytic control of genome integrity at the replication fork.

Authors:  Julie Rageul; Alexandra S Weinheimer; Jennifer J Park; Hyungjin Kim
Journal:  DNA Repair (Amst)       Date:  2019-07-10

Review 8.  Clinically Applicable Inhibitors Impacting Genome Stability.

Authors:  Anu Prakash; Juan F Garcia-Moreno; James A L Brown; Emer Bourke
Journal:  Molecules       Date:  2018-05-13       Impact factor: 4.411

9.  Structural basis for allosteric PARP-1 retention on DNA breaks.

Authors:  Levani Zandarashvili; Marie-France Langelier; Uday Kiran Velagapudi; Mark A Hancock; Jamin D Steffen; Ramya Billur; Zain M Hannan; Andrew J Wicks; Dragomir B Krastev; Stephen J Pettitt; Christopher J Lord; Tanaji T Talele; John M Pascal; Ben E Black
Journal:  Science       Date:  2020-04-03       Impact factor: 47.728

10.  Nanoemulsion-Based Delivery of Fluorescent PARP Inhibitors in Mouse Models of Small Cell Lung Cancer.

Authors:  Junior Gonzales; Susanne Kossatz; Sheryl Roberts; Giacomo Pirovano; Christian Brand; Carlos Pérez-Medina; Patrick Donabedian; M Jason de la Cruz; Willem J M Mulder; Thomas Reiner
Journal:  Bioconjug Chem       Date:  2018-11-07       Impact factor: 4.774
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.